CCCC

Q: What is the price of C4 Therapeutics (CCCC) today?

The current price of C4 Therapeutics (CCCC) is $ 3.74, representing a 187.69% gain over the past year. The stock began the year trading around $ 1.91 and is currently priced at $ 3.74. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

Q: When does C4 Therapeutics (CCCC) pay dividends?

C4 Therapeutics (CCCC) did not pay dividends over the past year.

C4 Therapeutics Inc.

Price

$ 3.74

return (12m)

187.69%

p/e

-4.32

p/bv

1.91

DIVIDEND YIELD

0.00%

CCCC price

C4 Therapeutics

If you had invested

exposure

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

15 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment CCCC

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

32.16%

3 months

34.53%

1 year

187.69%

2 years

-31.75%

5 years

-89.88%

10 years

0.00%

Fundamentals CCCC

review the fundamentals of C4 Therapeutics shares

P/E

-4.32

Sector: -3.88 Industry: -3.88

P/S (PSR)

12.87

Sector: -4.22 Industry: -4.22

P/BV

1.91

Sector: 1.96 Industry: 1.96

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

-31.57%

Sector: -64.79% Industry: -64.79%

ROE

-44.32%

Sector: -65.33% Industry: -65.33%

ROIC

-94.28%

Sector: -2,907.20% Industry: -2,907.20%

NET MARGIN

-100.00%

Sector: -39.82% Industry: -39.82%

GROSS MARGIN

100.00%

Sector: 36.79% Industry: 36.79%

OPERATING MARGIN

-100.00%

Sector: -38.80% Industry: -38.80%

EV/EBITDA

-4.43

Sector: -3.99 Industry: -3.99

EV/EBIT

-4.35

Sector: -4.06 Industry: -4.06

PRICE-TO-ASSETS

1.36

Sector: 1.44 Industry: 1.44

BVPS

1.86

Sector: 1.91 Industry: 1.91

EPS

-0.82

Sector: -2.12 Industry: -2.12

EQUITY-TO-ASSETS RATIO

0.71

Sector: 0.43 Industry: 0.43

LIABILITIES / ASSETS

0.29

Sector: 0.40 Industry: 0.40

CAGR REVENUE 5 YEARS

-5.31%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

4.35%

Sector: - Industry: -

Fundamentals CCCC

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	26.67	6.91	25.92%	2.23%	$ 561.22 B	21.83%
PFE	19.36	1.60	8.29%	6.75%	$ 145.01 B	11.83%
ABBV	105.03	-57.74	-54.98%	3.12%	$ 381.79 B	5.79%
NVO	10.53	6.36	60.40%	4.15%	$ 199.76 B	37.15%
MRK	33.87	6.59	19.45%	2.71%	$ 302.60 B	13.59%
AZN	27.89	6.11	21.93%	1.71%	$ 289.71 B	17.19%
GILD	18.11	7.12	39.33%	2.37%	$ 166.88 B	30.99%
BMY	16.66	6.03	36.19%	4.20%	$ 121.18 B	15.01%
ZTS	12.98	10.61	81.75%	2.50%	$ 34.32 B	27.79%
REGN	15.02	2.11	14.08%	0.56%	$ 66.44 B	29.65%
HALO	23.11	36.70	158.82%	0.00%	$ 8.06 B	23.13%
AMGN	23.49	19.94	84.87%	2.85%	$ 183.22 B	20.96%
MCK	19.63	-112.06	-570.98%	0.41%	$ 93.46 B	1.18%
HRMY	12.01	1.92	16.00%	0.00%	$ 1.75 B	16.20%
VRTX	25.44	5.70	22.41%	0.00%	$ 110.37 B	35.51%
CAH	30.33	-17.65	-58.20%	1.02%	$ 47.16 B	0.62%
ADMA	11.76	4.98	42.37%	0.00%	$ 1.94 B	32.43%

Stock vs Indice Comparison Tool

If you had invested

years ago

2 years

5 years

10 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

CCCC Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT C4 Therapeutics

C4 Therapeutics Inc.

Average Investor10 user rating

4.0 (1 people)

United States

11 years

Founded: 2015

2020

Time since IPO - 6 years

99

Employees

C4 Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $448.56 Millions, with shareholders equity totaling $234.25 Millions.

The company employs approximately 99 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, C4 Therapeutics Inc. reported $34.86 Millions in revenue, generating net income of $-103.81 Millions.

Key financial metrics include a P/E ratio of -4.32, a price-to-book (P/B) ratio of 1.91, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker CCCC.

Market cap

$ 448.56 Millions

Net worth

$ 234.25 Millions

$ 234,250,000.00

Assets

$ 328.86 Millions

$ 328,860,000.00

Total Shares Outstanding

126.00 Millions

126,000,000

Average Daily Trading Volume

$ 2.81 Millions

$ 2,805,690.00

Sector

Health Care

Industry

Biotechnology

CCCC

CCCC revenue and profits

Financial Results CCCC

DRAG THE FRAME TO SEE MORE DATA

CCCC cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 756.47 6,76% (12M)

P/E

19.63

0.41%

ROE

-570.98%

P/BV

-112.06

CAH - Cardinal Health

$ 199.84 32,33% (12M)

P/E

30.33

1.02%

ROE

-58.20%

P/BV

-17.65

JNJ - Johnson & Johnson

$ 231.29 56,90% (12M)

P/E

26.67

2.23%

ROE

25.92%

P/BV

6.91

MRK - Merck & Co.

$ 120.24 63,56% (12M)

P/E

33.87

2.71%

ROE

19.45%

P/BV

6.59

AZN - AstraZeneca

$ 185.65 33,28% (12M)

P/E

27.89

1.71%

ROE

21.93%

P/BV

6.11

ABBV - AbbVie

$ 215.40 21,39% (12M)

P/E

105.03

3.12%

ROE

-54.98%

P/BV

-57.74

NVO - Novo Nordisk

$ 44.55 --31,91% (12M)

P/E

10.53

4.15%

ROE

60.40%

P/BV

6.36

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 756.47 6,76% (12 M)

P/L

19.63

0.41%

ROE

-570.98%

P/VP

-112.06

CAH - Cardinal Health

$ 199.84 32,33% (12 M)

P/L

30.33

1.02%

ROE

-58.20%

P/VP

-17.65

JNJ - Johnson & Johnson

$ 231.29 56,90% (12 M)

P/L

26.67

2.23%

ROE

25.92%

P/VP

6.91

MRK - Merck & Co.

$ 120.24 63,56% (12 M)

P/L

33.87

2.71%

ROE

19.45%

P/VP

6.59

AZN - AstraZeneca

$ 185.65 33,28% (12 M)

P/L

27.89

1.71%

ROE

21.93%

P/VP

6.11

ABBV - AbbVie

$ 215.40 21,39% (12 M)

P/L

105.03

3.12%

ROE

-54.98%

P/VP

-57.74

NVO - Novo Nordisk

$ 44.55 --31,91% (12 M)

P/L

10.53

4.15%

ROE

60.40%

P/VP

6.36

Frequently Asked Questions

What is the price of C4 Therapeutics (CCCC) today?

The current price of C4 Therapeutics (CCCC) is $ 3.74, representing a 187.69% gain over the past year. The stock began the year trading around $ 1.91 and is currently priced at $ 3.74. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does C4 Therapeutics (CCCC) pay dividends?

C4 Therapeutics (CCCC) did not pay dividends over the past year.

Is C4 Therapeutics (CCCC) a good investment?

C4 Therapeutics (CCCC) is currently trading at $ 3.74 with a P/E ratio of -4.32. This represents a -268% premium compared to its historical average P/E. Over the past year, the stock has gained 187.69 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 187.69%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy C4 Therapeutics (CCCC) stock?

You can buy C4 Therapeutics (CCCC) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol CCCC and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of C4 Therapeutics (CCCC) yield today?

Over the past month, C4 Therapeutics (CCCC) has returned 32.16% — 187.69% over the past year, and -89.88% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of C4 Therapeutics (CCCC) today at the current price of $ 3.74 your total investment would be $ 374.00.

Based on historical performance, the investment would have grown to approximately:

$ 1,075.96 after 1 year
$ 37.85 after 5 years
$ 374.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

CCCC

C4 Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment CCCC

review the fundamentals of C4 Therapeutics shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

current DY: 0.00%

5-year average DY: 0.00%

ABOUT C4 Therapeutics

C4 Therapeutics Inc.

United States

11 years

2020

99

PROFIT X PRICE CCCC

Financial Results CCCC

CCCC cash flow

Asset, Revenue and Profit Growth - CCCC

CCCC balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

Frequently Asked Questions